Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy

BMB Reports

Volumn 47, Issue 3, 2014, Pages 158-166

  Kee, Hyun Jung ^a   Cheong, Jae Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cancer metabolism; Cancer therapeutics; Glycolysis; Oxidative phosphorylation; Tumor bioenergetics

Indexed keywords

ANIMAL; ENERGY METABOLISM; GLYCOLYSIS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84896967300     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.3.273     Document Type: Article

References (74)

1. Ben-Haim, S. and Ell, P. (2009) 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J. Nucl. Med. 50, 88-99.
2. Vander Heiden, M. G., Cantley, L. C. and Thompson, C. B. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
3. Warburg, O. (1956) On respiratory impairment in cancer cells. Science 124, 269-270.
4. Cairns, R. A., Harris, I. S. and Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer. 11, 85-95.
5. Levine, A. J. and Puzio-Kuter, A. M. (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344.
6. Lunt, S. Y. and Vander Heiden, M. G. (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464.
7. Wellen, K. E. and Thompson, C. B. (2012) A two-way street: reciprocal regulation of metabolism and signalling. Nat. Rev. Mol. Cell Biol. 13, 270-276.
8. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. and Bilanges, B. (2010) The emerging mechanisms of isoform- specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341.
9. Engelman, J. A. (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562.
10. Dang, C. V., Le, A. and Gao, P. (2009) MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15, 6479-6483.
11. Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X. Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B. and Thompson, C. B. (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 105, 18782-18787.
12. Gao, P., Tchernyshyov, I., Chang, T. C., Lee, Y. S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T. and Dang, C. V. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765.
13. Barthel, A., Okino, S. T., Liao, J., Nakatani, K., Li, J., Whitlock, J. P., Jr. and Roth, R. A. (1999) Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J. Biol. Chem. 274, 20281-20286.
14. Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K., Markowitz, S., Zhou, S., Diaz, L. A., Jr., Velculescu, V. E., Lengauer, C., Kinzler, K. W., Vogelstein, B. and Papadopoulos, N. (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559.
15. Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., Yan, H., Wang, W., Chen, S., Viale, A., Zheng, H., Paik, J. H., Lim, C., Guimaraes, A. R., Martin, E. S., Chang, J., Hezel, A. F., Perry, S. R., Hu, J., Gan, B., Xiao, Y., Asara, J. M., Weissleder, R., Wang, Y. A., Chin, L., Cantley, L. C. and DePinho, R. A. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670.
16. Schwartzenberg-Bar-Yoseph, F., Armoni, M. and Karnieli, E. (2004) The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 64, 2627-2633.
17. Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., Gottlieb, E. and Vousden, K. H. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120.
18. Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A. and Feng, Z. (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. U. S. A. 107, 7455-7460.
19. Matoba, S., Kang, J. G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F. and Hwang, P. M. (2006) p53 regulates mitochondrial respiration. Science 312, 1650-1653.
20. Maiuri, M. C., Galluzzi, L., Morselli, E., Kepp, O., Malik, S. A. and Kroemer, G. (2010) Autophagy regulation by p53. Curr. Opin. Cell Biol. 22, 181-185.
21. Mor, I., Cheung, E. C. and Vousden, K. H. (2011) Control of glycolysis through regulation of PFK1: old friends and recent additions. Cold Spring Harb. Symp. Quant. Biol. 76, 211-216.
22. Reid, M. A., Wang, W. I., Rosales, K. R., Welliver, M. X., Pan, M. and Kong, M. (2013) The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol. Cell 50, 200-211.
23. Maddocks, O. D., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E. and Vousden, K. H. (2013) Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542-546.
24. Omar, H. A., Berman-Booty, L. and Weng, J. R. (2012) Energy restriction: stepping stones towards cancer therapy. Future Oncol. 8, 1503-1506.
25. Brown, J. (1962) Effects of 2-deoxyglucose on carbohydrate metablism: review of the literature and studies in the rat. Metabolism 11, 1098-1112.
26. Shutt, D. C., O'Dorisio, M. S., Aykin-Burns, N. and Spitz, D. R. (2010) 2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells. Cancer Biol. Ther. 9, 853-861.
27. Rowe, I., Chiaravalli, M., Mannella, V., Ulisse, V., Quilici, G., Pema, M., Song, X. W., Xu, H., Mari, S., Qian, F., Pei, Y., Musco, G. and Boletta, A. (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488-493.
28. Dwarakanath, B. S., Singh, D., Banerji, A. K., Sarin, R., Venkataramana, N. K., Jalali, R., Vishwanath, P. N., Mohanti, B. K., Tripathi, R. P., Kalia, V. K. and Jain, V. (2009) Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J. Cancer Res. Ther. 5(Suppl 1), S21-26.
29. Wolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., Hawkins, C. and Guha, A. (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 208, 313-326.
30. Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., 2nd, Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., Telang, S. and Chesney, J. (2013) Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol. Cancer Ther. 12, 1461-1470.
31. Nicholls, C., Pinto, A. R., Li, H., Li, L., Wang, L., Simpson, R. and Liu, J. P. (2012) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component. Proc. Natl. Acad. Sci. U. S. A. 109, 13308-13313.
32. Goldberg, M. S. and Sharp, P. A. (2012) Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 209, 217-224.
33. Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Vander Jagt, D. L., Semenza, G. L. and Dang, C. V. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U. S. A. 107, 2037-2042.
34. Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., Hines, J. and Chen, X. (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther. 11, 1672-1682.
35. Zhan, T., Digel, M., Kuch, E. M., Stremmel, W. and Fullekrug, J. (2011) Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J. Cell Biochem. 112, 849-859.
36. Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., Kelley, M. J., Gallez, B., Wahl, M. L., Feron, O. and Dewhirst, M. W. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942.
37. Whitaker-Menezes, D., Martinez-Outschoorn, U. E., Lin, Z., Ertel, A., Flomenberg, N., Witkiewicz, A. K., Birbe, R. C., Howell, A., Pavlides, S., Gandara, R., Pestell, R. G., Sotgia, F., Philp, N. J. and Lisanti, M. P. (2011) Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 10, 1772-1783.
38. Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M. A., Arumugam, S., Dean, W. L., Eaton, J., Lane, A., Trent, J. O. and Chesney, J. (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 7, 110-120.
39. Telang, S., Yalcin, A., Clem, A. L., Bucala, R., Lane, A. N., Eaton, J. W. and Chesney, J. (2006) Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 25, 7225-7234.
40. Kumagai, S., Narasaki, R. and Hasumi, K. (2008) Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells. Biochem. Biophys. Res. Commun. 365, 362-368.
41. Shoshan, M. C. (2012) 3-Bromopyruvate: targets and outcomes. J. Bioenerg. Biomembr. 44, 7-15.
42. Goldin, N., Arzoine, L., Heyfets, A., Israelson, A., Zaslavsky, Z., Bravman, T., Bronner, V., Notcovich, A., Shoshan-Barmatz, V. and Flescher, E. (2008) Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27, 4636-4643.
43. Birsoy, K., Wang, T., Possemato, R., Yilmaz, O. H., Koch, C. E., Chen, W. W., Hutchins, A. W., Gultekin, Y., Peterson, T. R., Carette, J. E., Brummelkamp, T. R., Clish, C. B. and Sabatini, D. M. (2013) MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45, 104-108.
44. Mohanti, B. K., Rath, G. K., Anantha, N., Kannan, V., Das, B. S., Chandramouli, B. A., Banerjee, A. K., Das, S., Jena, A., Ravichandran, R., Sahi, U. P., Kumar, R., Kapoor, N., Kalia, V. K., Dwarakanath, B. S. and Jain, V. (1996) Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 35, 103-111.
45. Mathupala, S. P., Ko, Y. H. and Pedersen, P. L. (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin. Cancer Biol. 19, 17-24.
46. Hamanaka, R. B. and Chandel, N. S. (2012) Targeting glucose metabolism for cancer therapy. J. Exp. Med. 209, 211-215.
47. Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J. K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., Yang, H., Mattaini, K. R., Metallo, C. M., Fiske, B. P., Courtney, K. D., Malstrom, S., Khan, T. M., Kung, C., Skoumbourdis, A. P., Veith, H., Southall, N., Walsh, M. J., Brimacombe, K. R., Leister, W., Lunt, S. Y., Johnson, Z. R., Yen, K. E., Kunii, K., Davidson, S. M., Christofk, H. R., Austin, C. P., Inglese, J., Harris, M. H., Asara, J. M., Stephanopoulos, G., Salituro, F. G., Jin, S., Dang, L., Auld, D. S., Park, H. W., Cantley, L. C., Thomas, C. J. and Vander Heiden, M. G. (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839-847.
48. Cortes-Cros, M., Hemmerlin, C., Ferretti, S., Zhang, J., Gounarides, J. S., Yin, H., Muller, A., Haberkorn, A., Chene, P., Sellers, W. R. and Hofmann, F. (2013) M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc. Natl. Acad. Sci. U. S. A. 110, 489-494.
49. DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S. and Thompson, C. B. (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U. S. A. 104, 19345-19350.
50. Wise, D. R. and Thompson, C. B. (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427-433.
51. Wang, J. B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L., Dias, S. M., Dang, C. V. and Cerione, R. A. (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219.
52. Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., Dang, C. V. and Riggins, G. J. (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70, 8981-8987.
53. Yang, C., Sudderth, J., Dang, T., Bachoo, R. M., McDonald, J. G. and DeBerardinis, R. J. (2009) Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 69, 7986-7993.
54. Holubarsch, C. J., Rohrbach, M., Karrasch, M., Boehm, E., Polonski, L., Ponikowski, P. and Rhein, S. (2007) A double- blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin. Sci. (Lond) 113, 205-212.
55. Downey, R. J., Akhurst, T., Gonen, M., Vincent, A., Bains, M. S., Larson, S. and Rusch, V. (2004) Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J. Clin. Oncol. 22, 3255-3260.
56. Aykin-Burns, N., Ahmad, I. M., Zhu, Y., Oberley, L. W. and Spitz, D. R. (2009) Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem. J. 418, 29-37.
57. Singh, D., Banerji, A. K., Dwarakanath, B. S., Tripathi, R. P., Gupta, J. P., Mathew, T. L., Ravindranath, T. and Jain, V. (2005) Optimizing cancer radiotherapy with 2-deoxy- d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 181, 507-514.
58. Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., Dipaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., Kroll, S., Jung, D. T., Kurtoglu, M., Rosenblatt, J. and Lampidis, T. J. (2013) A phase I dose-escalation trial of 2-deoxy- D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71, 523-530.
59. Kaplan, O., Navon, G., Lyon, R. C., Faustino, P. J., Straka, E. J. and Cohen, J. S. (1990) Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res. 50, 544-551.
60. Cay, O., Radnell, M., Jeppsson, B., Ahren, B. and Bengmark, S. (1992) Inhibitory effect of 2-deoxy-D-glucose on liver tumor growth in rats. Cancer Res. 52, 5794-5796.
61. Cheong, J. H., Park, E. S., Liang, J., Dennison, J. B., Tsavachidou, D., Nguyen-Charles, C., Wa Cheng, K., Hall, H., Zhang, D., Lu, Y., Ravoori, M., Kundra, V., Ajani, J., Lee, J. S., Ki Hong, W. and Mills, G. B. (2011) Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 10, 2350-2362.
62. Hardie, D. G. (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774-785.
63. Hardie, D. G., Ross, F. A. and Hawley, S. A. (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251-262.
64. Chhipa, R. R., Wu, Y., Mohler, J. L. and Ip, C. (2010) Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal. 22, 1554-1561.
65. Shaw, R. J. and Cantley, L. C. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430.
66. Beckers, A., Organe, S., Timmermans, L., Scheys, K., Peeters, A., Brusselmans, K., Verhoeven, G. and Swinnen, J. V. (2007) Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67, 8180-8187.
67. Ahn, Y. J., Kim, H., Lim, H., Lee, M., Kang, Y., Moon, S., Kim, H. S. and Kim, H. H. (2012) AMP-activated protein kinase: implications on ischemic diseases. BMB Rep. 45, 489-495.
68. Graham, N. A., Tahmasian, M., Kohli, B., Komisopoulou, E., Zhu, M., Vivanco, I., Teitell, M. A., Wu, H., Ribas, A., Lo, R. S., Mellinghoff, I. K., Mischel, P. S. and Graeber, T. G. (2012) Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol. Syst. Biol. 8, 589.
69. Choo, A. Y., Kim, S. G., Vander Heiden, M. G., Mahoney, S. J., Vu, H., Yoon, S. O., Cantley, L. C. and Blenis, J. (2010) Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol. Cell 38, 487-499.
70. Laderoute, K. R., Amin, K., Calaoagan, J. M., Knapp, M., Le, T., Orduna, J., Foretz, M. and Viollet, B. (2006) 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol. Cell Biol. 26, 5336-5347.
71. Ben Sahra, I., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P., Le Marchand-Brustel, Y., Giorgetti-Peraldi, S., Cormont, M., Bertolotto, C., Deckert, M., Auberger, P., Tanti, J. F. and Bost, F. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70, 2465-2475.
72. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. and Morris, A. D. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305.
73. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J. and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174.
74. Saito, S., Furuno, A., Sakurai, J., Sakamoto, A., Park, H. R., Shin-Ya, K., Tsuruo, T. and Tomida, A. (2009) Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res. 69, 4225-4234.